Mangalam Drugs and Organics Limited announced the outcome of its board meeting held on September 15, 2026, detailing the appointment of Mr. Prabhakar Raghunath Zavar as an Additional Director in the capacity of Non-Executive Independent Director for a consecutive term of five years.

The notice outlines that the appointment of Mr. Prabhakar Raghunath Zavar was considered and approved by the Board of Directors following the recommendation of the Nomination and Remuneration Committee, effective from September 15, 2026, subject to approval from shareholders at the upcoming Extra-Ordinary General Meeting. Mr. Zavar brings over 38 years of professional experience spanning accounts, finance, and taxation, with extensive expertise in international trade and export-oriented businesses.

Mangalam Drugs and Organics Limited is an established player in the pharmaceutical sector, specialized in manufacturing active pharmaceutical ingredients (APIs), bulk drugs, and intermediates—notably anti-malarial products. During 2025, the company expanded its global footprint by securing significant repeat international export orders, including an approx. Rs. 15 crore export order for anti-malarial APIs announced in late 2025. These developments continue to boost the company’s global standing and revenue visibility.

Financially, the company experienced mixed metrics over recent quarterly disclosures in 2025, reflecting typical industry dynamics and raw material fluctuations. Prominently, the microcap firm caught the attention of market participants when ace investor Vijay Kedia’s firm, Kedia Securities, acquired a notable stake via bulk deals in late December 2025.